Good morning and welcome to AirSculpt Technologies Second Quarter 2022 Earnings Conference Call. Currently, all participants are in a listen-only mode. As a reminder, today's call is being recorded, and we have allocated one hour for prepared remarks and Q&A. At this time, I'd like to turn the conference over to Dennis Dean, Chief Financial Officer at AirSculpt Technologies. Thank you. You may begin.

Good morning, everyone, and thanks for joining us to discuss AirSculpt Technologies results for the first quarter. Joining me on the call today is our Founder and Chief Executive Officer, Dr. Aaron Rollins, and our Chief Operating Officer, Ron Zelhof. Before we begin, I would like to remind you that this conference call may include forward-looking statements. These statements may include our future expectations regarding financial results and guidance, market opportunities, and our growth. Risk and uncertainties that may impact these statements and could cause actual future results to differ materially from currently projected results are described in this morning's press release, and the reports we will file with the SEC, all of which can be found on our website at investors.elitebodysculpture.com. We undertake no obligation to revise or update any forward-looking statements or information except as required by law. During our call today, we will also reference certain non-GAAP financial measures. We use non-GAAP measures in some of our financial discussions, as we believe they more accurately represent the true operational performance and underlying results of our business. A reconciliation of these measures can be found in our earnings release, as filed this morning, and in our most recent quarterly report when filed, which will also be available on our website. Now I'm going to turn the call over to Dr. Rollins.

Thank you, Dennis. Good morning. And thank you all for joining us today. I'm happy to say once again, the second quarter saw us reach the highest quarterly volume and revenue ever achieved in our history. For the quarter, we generated $49.7 million in revenue, reflecting a growth of 42% over the prior-year quarter. During the quarter, we reached an exciting milestone, performing over 30,000 AirSculpt cases since our founding a decade ago. We take immense pride in improving the lives of our patients while providing excellent care. Previously, we announced the health research study we are undertaking on the effects our procedures have on a patient's metabolic parameters. Recently, we submitted our study to the Institutional Review Board for approval. Once we receive final approval from the IRB, we will begin enrolling patients, which we expect to occur later this year, and we still anticipate having results for the study in 2023. We also recently opened our Boston center and expect to open Philadelphia later in the third quarter. Moreover, we expect our first international site in Toronto to open later this year, once we receive final government approvals. As we have said on previous calls, we believe there are great opportunities to further expand our network of centers internationally while still maintaining our growth domestically. We are excited about the vast number of opportunities in front of us, and we look forward to capitalizing on these opportunities as we continue to deliver exceptional results to our patients. We also remain committed to building out our team to support our rapid growth. We have been heavily focused on our clinical and operations infrastructure to manage our growth domestically and as we expand our global presence. Before I turn the call over to Ron, I want to also comment on the special dividend we are announcing this morning. We believe this dividend provides a meaningful cash return to our shareholders and underscores our confidence in the business and our balance sheet, as we are funding the dividend with excess cash from our balance sheet. This will not impact our gross leverage.

Thank you, Dr. Rollins. And good morning, everyone. I'm going to provide you with a development update regarding our de novo activity and procedure room expansion projects. As previously reported, our center in Las Vegas opened in March of this year, and we opened our newest location in Boston during the month of July. We have now opened four centers in the past seven months, which demonstrates our ability to execute our de novo strategy at a rapid pace, and each center is performing well. We expect our center in Philadelphia to become operational in September, and our Toronto location later in the fourth quarter, once we finalize regulatory approval. We have also secured space in Austin, Texas, and Irvine, California, which will likely be our next domestic sites. We anticipate these centers to open in the first half of 2023, and we are diligently working on accelerating our new center openings for the rest of 2023 and 2024. We look forward to sharing more about those markets in the coming months. We have a desire to grow at an even faster pace, but our top priority is to maintain exceptional quality and safety for our patients. As Dr. Rollins mentioned, we continue making investments in our support teams to accelerate our growth plans. Finally, I am pleased to announce that we have now completed our procedure room expansion projects on existing centers. All of our centers now have at least two procedure rooms, and at three locations, we have three procedure rooms. It has been a busy first half of the year, and these expansions, along with the new center openings, put us on a great path for continued growth. With that, I'll turn it back over to Dennis to provide additional details on our financial results.

Thanks, Ron. First, I want to comment on the confidence we have in the strength of our business and our ability to sustain long-term growth. We continue to focus on making investments that are essential to our growth initiatives while also delivering exceptional returns on capital. During the quarter, our revenue increased by $14.7 million to $49.7 million, a 42% increase from the prior-year quarter, and our cases increased by 22.5% to 3,691. The increase is primarily a result of adding four de novo centers over the prior-year quarter, which expanded our footprint to 19 centers as of June 30, 2022. Our revenue per case was $13,453, a 16% increase from the prior-year quarter. We continue to be pleased with our average revenue per case increases, which are due to patients continuing to have more areas treated at once. Our same-center revenue increased approximately 20% over the prior period, comprised of a volume increase of approximately 5% and a revenue per case increase of 15%. Our same-store growth can be attributed to favorable trends in the aesthetic space and to expanding our marketing and selling capabilities to increase brand awareness and attract more patients into our centers. Our cost of service as a percentage of revenue was 35.2% versus 32.1% in the same period last year. As we mentioned on previous calls, we have been making clinical staffing additions to proactively prepare for accelerating our growth plans, and as expected, we began to leverage some of those investments during the second quarter, as our nursing costs as a percentage of revenue declined by 100 basis points compared to the first quarter of 2022. As Ron mentioned in his remarks, we have opened four de novos in the past seven months, which negatively impacted our margins in the quarter by approximately 80 basis points. This is an improvement from the 130 basis point impact reported in the first quarter, and we anticipate margins will continue to improve as the de novos ramp up in case volume. Our total customer acquisition cost for the quarter was approximately $2,000 per customer, and as expected, it was down sequentially from $2,200 per customer in the first quarter of 2022. Our adjusted EBITDA was $15.2 million for the quarter. Adjusted EBITDA included approximately $1.9 million of public company-related costs which did not exist in the prior-year quarter as we were a private company. Normalizing the prior year to include these public company costs, our adjusted EBITDA growth rate would have been approximately 24%, and the adjusted EBITDA margin for the second quarter was 30.7%, which represents a sequential increase of 590 basis points from the first quarter of 2022. Moving on to liquidity, our cash position as of June 30 was $35.3 million, and our $5 million revolver remains undrawn. Our long-term debt was approximately $83 million, and our leverage ratio at the end of the quarter, as calculated under our credit agreement, was 1.6 times. Cash flow from operations for the quarter amounted to $10.4 million, which reflects approximately 68% adjusted EBITDA to cash conversion. As a reminder, we carry no accounts receivable as we receive 100% payment upfront, and our cost structure is highly variable, as our surgeons receive payment only after a surgery is performed. We invested $1.9 million during the quarter, primarily related to opening our center in Boston, and our upcoming opening in Philadelphia, along with our procedure room expansion projects. We are reiterating our revenue guidance range of $175 million to $179 million for the full year, which represents a 31% to 34% increase over 2021 levels. In addition, we are maintaining our adjusted EBITDA outlook of $58 million to $60 million. Finally, as we announced in this morning's release, our board has approved a special dividend of $0.41 per share to be paid to shareholders of record as of August 26, 2022, with a payment date of September 14, 2022. We believe this special dividend demonstrates our confidence in the growth of our business. Due to our ability to deliver excellent free cash flow and the modest cost of opening new centers, this special dividend will not compromise our ability to deliver significant growth in the future, while allowing us to provide cash returns to our shareholders by using excess cash from operations without increasing our gross leverage. With that, I'll turn the call over to the operator for a few questions.

Our first question comes from Josh Raskin with Nephron Research.

I think, last quarter, you had suggested revenues would be in that mid-40s range for the second quarter, always a seasonally strong quarter. But, obviously, a lot of upside in the quarter. So I'm curious if you could just sort of talk to some of the upside and some of the drivers for that. And then, as I think about guidance, it doesn't look like you're assuming much of that flows through the second half. So, maybe other than conservatism, is there anything we should be thinking about potential headwinds for the second half?

It's Aaron Rollins. We aren't giving specific quarterly outlook. And we really are just reiterating our full guidance on both revenue and EBITDA. We remain very excited about the business, and the de novos are coming online and ramping up per expectations.

This is Dennis. And I wanted to just add to that, too. We had some improvement in our rate during the quarter as well. And as we've talked about, our rate can bounce around from quarter to quarter based on the areas our patients get treated and things of that nature. So we had some improvement there sequentially that also lifted the revenue numbers for the quarter.

Just a quick follow-up. Did you guys think about share buybacks instead of the special dividend? And maybe what makes the dividend the most attractive option to return to shareholders?

Josh, we looked at a couple of different options for us. We felt the dividend was the best thing for us for this time period. We don't have a significant amount of public float, as it relates to that. We did consider the buyback option. We just didn't think that was the best option at this point. It may be something we look at in the future, depending on where things shake out, but we felt like the dividend was something to demonstrate our confidence in the business, our ability to generate a significant amount of free cash flow. And again, we're very excited we can do it without putting any additional debt on the balance sheet.

Our next question comes from line of Korinne Wolfmeyer with Piper Sandler.

Congrats on the quarter. So I'd like to push you a little bit more on that previous question there on the back half of the year. Now that we're a little bit farther into Q3, is there any insights you can provide on how demand has been trending? I know there's been a lot of talk, given the inflationary impact on consumers and how that may impact demand. Is there just any color you can provide on how you're thinking about that for AirSculpt for the back half of the year?

Korinne, again, without giving quarterly type guidance, reiterating our revenue numbers for the outlook is something we're very confident in. Obviously, Q2 was very strong for us, and we feel really good about where we are.

I'd like to add that we get patients from multiple income brackets, but our marketing strategy is geared toward the upper middle class and above, and they tend to be more resilient to challenging economic conditions.

Just as we start thinking about bringing on more and more centers come 2023, and now that you're finishing up adding additional rooms to the 15 centers, now that that's over with, how should we be thinking about the cadence of door openings going forward? Are we still targeting like three to four? And then kind of related, on the Toronto facility, is there any risk of not receiving government approval for Toronto? Or what is the process there?

It's Ron. On your first question, as I said in the remarks earlier, we look forward to and we want to go ahead and increase our openings. However, our guidance is still sitting at three to four. As we mentioned, we've done basically eight this year, with the four as well as expanding our procedure rooms from one to multiple rooms this year. So we're set up for it. We know everybody wants in, and that's what we're shooting for. In terms of Toronto, there's no risk. It's just a timing issue at this point.

Our next question comes from line of John Ransom with Raymond James.

If we look at the G&A and the revenue per procedure this quarter, Dennis, is that kind of how we should think about the balance of the year?

On a G&A perspective, John, I think that's where we should sort of shake out the remainder of the year. Obviously, our marketing costs which you may or may not be including that in there, if you're thinking about the total numbers. We've made significant investments in the first half of the year in our infrastructure teams. And we've recently brought on one new executive in July that's going to be focusing on the branding aspects of marketing. But for the most part, our G&A, we feel like we've gotten the majority of our support teams in place and expect to begin to leverage that even further as we move through this year, as well as into next for sure.

And then revenue per procedure, anything to call out on the quarter or a reason I think that wouldn't continue through the year?

We've talked about this on a number of quarters now that that revenue per case number can bounce quite a bit, depending on the patients that come in, what procedures they have performed, what areas and things of that nature. We feel like we're beginning to sort of max out to some degree in the revenue per case number. If the number were to drop down sub $13,000, it wouldn't necessarily shock us right now because, again, we're still a pretty small volume business. But as we continue to grow that footprint, that number is going to become more and more stable. We are working on some things internally about possibly additional types of things in the future that could potentially give us a little bit of impact on the revenue per procedure.

Just lastly for me, I'll get back in queue, obviously, the market went crazy with recession concerns. Just remind us how far out your visibility is on your bookings.

On our bookings, John, we don't have a significant backlog. In our procedure, one of the things that we really have focused on over the last eight to nine months is really getting patients scheduled quicker. One of the things that gave us backlog historically was that a significant number of our centers were single procedure room centers, those legacy facilities that Dr. Rollins started with. Those centers were the ones where we had what we would have considered backlogs that we didn't necessarily feel comfortable with. But now that every one of those has been expanded, it allows us to get patients treated really quickly, so we never expect now a significant backlog because, as a center kind of gets to the point of a utilization that we think we need to begin to expand again, we'll do that as well.

Our next question comes from line of Whit Mayo with SVB Securities.

When I look at the rate per case on the non-same store centers, it's running pretty high, north of $14,000. Is there anything unique about the new centers that's driving that? I just presume it's higher demand for the fat transfers, which presumably is good as we think out over the next year as those roll into the same-store count. But just wondering if there's any learnings or early observations on the new center openings that you have anything that maybe surprised you good or bad?

From a rate perspective, there's nothing that we would necessarily want to call out, or that really surprised us one way or the other on the same-store group or the new center group. Again, those numbers can bounce from quarter to quarter on a per-case rate basis, but what I would say is, obviously, we're very pleased with where we are from a rate and we feel good about it.

Just any additional observations as you just sort of reflect back on the recent centers that opened where you say, wow, like, we've really got this kind of figured out or, like, this kind of surprised us? Just anything that surprised you one way or another?

No, not at all. They're all doing very well. And we continue to be extremely excited about our openings right now. The newest ones are going according to plan, and there have been no surprises.

Yeah, I think it just kind of reiterates our confidence in all the markets that we go into. Whether they be larger markets or mid-markets, they're all performing well.

I would say that the more we do this, the better we get at it. The smoother it goes and the easier the ramp-up is, I'd say.

And part of that is we're expanding our support team to help us...

...infrastructure.

...as Ron said, to accelerate the opportunities that are out in front of us.

And maybe just finally, to follow up on that, you have accelerated some of those investments in the infrastructures as you sort of referenced in the last six months. And you talked about the higher G&A, Dennis, the new marketing head, the new physician training person, or recruiting whatever we're calling the title, but any success stories that you can talk about there, any early returns that you believe you're seeing other than perhaps some of the performance of the new centers? Just anything else that might be helpful?

Actually, so we have two full-time surgeon trainers. One is based on the West Coast and one is based on the East Coast. And we're doing a really good job with physician recruitment. Because we are hiring so many doctors, both for existing centers that have expanded and for new centers, our needs for training are being met. We're able to train these doctors very well and thoroughly, and get them going faster, more efficiently, and honestly, at clinical quality than we could before. So that's a big improvement since we've gone public.

I'd also like to add that in terms of our expansion of our legacy one-room centers, we mentioned that it would be done by the end of the year, and we've already completed our expansion projects.

So it's helped us there as well.

Our next question comes from line of Simeon Gutman with Morgan Stanley.

Can I ask about utilization or center utilization, how it's performing? I realize you've added capacity? And then, do you have a sense of where that ceiling may be?

Normalized for the new centers and procedure rooms, we're approximately 45%. Right now, just to give you the estimate, our full capacity is at 85%, Simeon. So that's where we stand right now. And again, from a procedure room count as of June 30, we were at 38 procedure rooms.

I wanted to ask about the revenue per case. You mentioned it could fluctuate, but we might be reaching some type of high point on it. I don't think we have the comparisons, I think, to last year. So, we try to look at it on a stack basis. One, I guess, is it accelerating? We don't see what the underlying trend is. And two, that means in the revenue per case component, we shouldn't assume much higher than what we hit this quarter going forward.

Simeon, last year, second quarter, we were at $11,600 per case. Again, this quarter, we were at $13,400. We've talked a number of times how we really, over the last year, have gotten a lot of benefits we believe from AirSculpt TV and really educating the consumer to get more areas done at once. That's uplifted our rates. There's no exact science here. Some of it's a little bit of a feel as it relates to where we are. I'm not modeling significant increases on top of where we are right now. And again, I kind of use that range of upper 12s to mid-13s as a range to kind of look for. But again, a case isn't a case. Sometimes when your rate may go up, your volume may tick down just a little bit because you're spending more time with a patient in a procedure room, and vice versa.

Our next question is a follow-up from John Ransom with Raymond James.

You know this is my favorite topic. As you expand your footprint and your resources improve, as we think about the intermediate term, what does the marketing and customer acquisition look like six months a year from now that may or may not be different from what you've done historically?

As you know, we hired a chief marketing officer/branding officer in July, and we're really excited about her. She's hit the ground running. We're down the road with two potential big celebrities. We're working really hard at getting PR that's not celebrity focused. It's based on what we do and other forms of marketing that we'll be launching soon. Right now, we have a strong return on our customer acquisition costs, with gross margin per case in excess of $8,000 per patient. So we're getting a 4x return on our CAC. And customer acquisition cost was down, at $2,000, down from $2,200. I do think that customer acquisition costs, at least for the time being, while we gear up, what I like to say, other legs of the marketing table, will fluctuate. It all depends right now on how many people are bidding for the same leads on Google. The more people that we're competing against, the more the costs and vice versa.

I appreciate you including me in your celebrity, one of the two. I need to return her call. I'm kidding, everybody. I'm kidding. You've talked in the past about some longer-term initiatives around storing stem cells and quantifying health benefits. So, just an update on those would be great.

Well, we have started the stem cell initiative. And it's just to allow patients to bank their stem cells, if they wish. And it's a wellness thing. It's not something we're trying to make money on. We want to provide the absolute best service possible to our patients. We think that's an important option to offer them. It's something that's being rolled out slowly, and we really haven't made a verdict on whether or not we'll roll it out completely. It just depends on if patients want to do it or not. On the metabolic study, we're proceeding according to the timing we set. We submitted the study to the IRB. We're waiting for final approval. We expect to enroll patients later this year, likely in the fall, with results expected in 2023. That's what we've talked about thus far.

We have reached the end of the question-and-answer session. I would now like to turn the floor back over to Dr. Rollins for closing comments.

I just want to thank everyone for listening to the call today. And I want to thank my incredible team that is performing so well. I can't tell you how proud I am to offer this special dividend. We remain incredibly focused on shareholder value and building this business. Thanks again.

Ladies and gentlemen, this does conclude today's teleconference. You may disconnect your lines at this time. Thank you for your participation and have a wonderful day.